Celebrate Memorial Day with a special offer from Benzinga Pro. For a limited time, you can take advantage of our 50% discount and gain access to exclusive market-moving news for your family. Secure your financial freedom by claiming your discount here.
Sharps Technology Inc (NASDAQ: STSS) shares saw a 39.8% increase to $0.63 on Thursday following the announcement of a 5-year $200 million syringe sales agreement with Nephron Pharmaceuticals. This deal complements Sharps Technology’s recent acquisition of InjectEZ specialty syringe manufacturing assets in South Carolina. The facility will be the only dedicated COC prefillable syringe manufacturing plant in North America, with advanced production capabilities. Product delivery is expected to begin in late second-quarter 2025, generating an estimated revenue of around $37 million in the first year.
If you want to invest in STSS stock, there are several options available to you. You can visit a brokerage platform and purchase shares directly or consider investing in an exchange-traded fund (ETF) that holds the stock. Another option is to allocate funds in your 401(k) to a strategy that involves acquiring shares in a mutual fund or other investment instrument. For example, Sharps Technology operates in the Health Care sector, so investing in an ETF that tracks this sector can provide exposure to industry trends. Benzinga Pro data shows that STSS has a 52-week high of $1.05 and a 52-week low of $0.17.
Take advantage of our Memorial Day Flash Sale offering 50% off Benzinga Pro to get exclusive market moving news at unbeatable prices! Investing in stocks can be daunting but with Benzinga’s help, you can make informed decisions about your investments.
As always, remember that Benzinga does not offer investment advice and all rights are reserved.
Enter to win $500 in stock or crypto by providing your email and signing up for Benzinga’s morning update.
The information provided above should not be considered as financial advice
